Value Partners, Insilico Medicine, Pudong jointly launch ‘AI+Life Sciences’ CVC fund Hong Kong Standard 16:05 Tue, 18 Aug
Insilico Medicine Launches Virtual Aging Cell Platform For Drug Discovery Scrip Pharma Intelligence 12:25 Tue, 18 Aug
Insilico Medicine Included in MSCI Global Small Cap Index, Recognized for Core Strengths in Capital Markets China Money Network 15:28 Mon, 17 Aug
Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths PR Newswire (Press Release) 13:36 Mon, 17 Aug
Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual Aging Cell Webpage and Previews Multi-Agent Driven Vac Generation Platform PR Newswire (Press Release) 14:14 Fri, 14 Aug
AI-Empowered Pipeline-In-A-Drug Option: Insilico Medicine Nominates ISM9077, Potential First-In-Class Target Y Inhibitor, As Preclinical Candidate (PCC) For Ocular Diseases, Inflammatory Disorders And Aging Drugs Discovery Online 08:52 Thu, 13 Aug
Insilico Medicine nominates powerful oral drug candidate for the management of heart risks News-Medical.Net 18:22 Wed, 12 Aug
Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks PR Newswire (Press Release) 13:31 Wed, 12 Aug
Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates PR Newswire (Press Release) 10:47 Tue, 11 Aug
Insilico Medicine nominates AI-designed candidate for ocular diseases Drug Target Review 14:23 Mon, 10 Aug
Insilico Medicine highlights AI-powered biological target discovery for rare sinonasal cancer News-Medical.Net 17:05 Tue, 04 Aug
Insilico Medicine launches AI drug discovery benchmarking platform Drug Target Review 13:38 Fri, 31 Jul
Insilico Medicine Launches the Industry's First Drug Discovery and Development (Ddd) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science PR Newswire (Press Release) 14:05 Thu, 30 Jul
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-Tead Inhibitor, in Advanced Mesothelioma PR Newswire (Press Release) 13:32 Wed, 29 Jul
Insilico Medicine Announces Oral Presentation at Esmo 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors PR Newswire (Press Release) 13:04 Mon, 27 Jul
Insilico Medicine nominates ISM9528 non-opioid chronic pain candidate using AI Drug Target Review 14:24 Thu, 23 Jul
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management PR Newswire (Press Release) 14:00 Wed, 22 Jul
